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The renin-angiotensin-aldosterone system (RAAS) plays a key role in the pathogenesis
of cardiovascular disorders including hypertension and is one of the most important tar-
gets for drugs. A whole body physiologically based pharmacokinetic (wb PBPK) model
integrating this hormone circulation system and its inhibition can be used to explore the
influence of drugs that interfere with this system, and thus to improve the understand-
ing of interactions between drugs and the target system. In this study, we describe the
development of a mechanistic RAAS model and exemplify drug action by a simulation of
enalapril administration. Enalapril and its metabolite enalaprilat are potent inhibitors of the
angiotensin-converting-enzyme (ACE). To this end, a coupled dynamic parent-metabolite
PBPK model was developed and linked with the RAAS model that consists of seven coupled
PBPK models for aldosterone, ACE, angiotensin 1, angiotensin 2, angiotensin 2 receptor
type 1, renin, and prorenin.The results indicate that the model represents the interactions
in the RAAS in response to the pharmacokinetics (PK) and pharmacodynamics (PD) of
enalapril and enalaprilat in an accurate manner. The full set of RAAS-hormone profiles and
interactions are consistently described at pre- and post-administration steady state as well
as during their dynamic transition and show a good agreement with literature data. The
model allows a simultaneous representation of the parent-metabolite conversion to the
active form as well as the effect of the drug on the hormone levels, offering a detailed
mechanistic insight into the hormone cascade and its inhibition. This model constitutes a
first major step to establish a PBPK-PD-model including the PK and the mode of action
(MoA) of a drug acting on a dynamic RAAS that can be further used to link to clinical
endpoints such as blood pressure.
Keywords: physiologically based pharmacokinetic model, cardiovascular, renin-angiotensin-aldosterone system,
enalapril, enalaprilat
INTRODUCTION
Hypertension is a worldwide epidemic, which affects all ages
and racial populations. It has a very high incidence and is the
leading cause of cardiovascular mortality (Roger et al., 2012).
There is still a lack of mechanistic models in the published
literature that integrate the available physiological knowledge
and relate the pharmacokinetics (PK) of hypertension drugs to
their pharmacodynamics (PD) effects. One model addressing
among others the RAAS and the blood pressure, is the Guy-
ton’s physiological model (Guyton et al., 1972), it was extended
and published recently (Montani and Van Vliet, 2009; Osborn
et al., 2009). Although this and other models may contain all
the parameters listed in this present study and although they
might have been validated against several physiological situa-
tions they are not based on a generic whole body physiologi-
cally based PK (wb PBPK) background model. Other approaches
concerning the hormone cascade, as for example by White
et al. (1989), Levitt and Schoemaker (2006), Guillaud and Han-
naert (2010), Zhou et al. (2012), have different focuses or
approaches.
To overcome the lack of detailed physiologically based mod-
els for cardiovascular PD, we aimed to establish a mechanistic
model for the RAAS covering all relevant biological processes
depicted in Figure 1. Renin is synthesized from the enzyme
precursor prorenin, which is produced mainly in the kidney
and secreted into the plasma by the granular cells (Krop et al.,
2008). The active enzyme renin is stored in the cells of the
juxtaglomerular apparatus is released immediately on stimula-
tion of these cells (Danser et al., 1998). After secretion into the
plasma, renin converts the hepatically synthesized inactive hor-
mone angiotensinogen (AGT) to angiotensin 1 (Ang1). Ang1 is
then converted in the plasma compartment by the membrane
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bound angiotensin-converting-enzyme (ACE), expressed by the
vascular endothelium, to angiotensin 2 (Ang2). Ang2 has an
inhibiting effect on renin synthesis and secretion and thus on
the plasma levels of Ang1 and Ang2 (Johns et al., 1990). Ang2
is a vasoactive peptide that induces volume (and Na) retain-
ing effects as well as vasoconstricting effects and an increase in
blood volume, leading to increased blood pressure. It potenti-
ates aldosterone secretion by interacting with its angiotensin 2
receptor type 1 (AT1). Aldosterone increases the blood pressure
as well (Gornall et al., 1960) by sodium and extracellular vol-
ume retention. Several cardiovascular disease states are associated
with changes in circulating Ang2 (Laragh et al., 1972; Laragh,
1995).
Inhibitors of the RAAS can be classified by their mode of action
(MoA; Cagnoni et al., 2010; Eisenberg, 2011; Aronson and Krum,
2012) into five categories:
FIGURE 1 | Schematic representation of the
renin-angiotensin-aldosterone system (RAAS). Renin converts
the hepatically secreted angiotensinogen (AGT) to angiotensin 1
(Ang1). Ang1 is then converted to angiotensin 2 (Ang2) by the
membrane bound angiotensin-converting-enzyme (ACE). Ang2 then
binds to the angiotensin 2 receptor type 1 (AT1). The most important
effects of AT1 binding are depicted either: the aldosterone secretion
by the adrenals and the inhibition of renin activation from prorenin.
Different processes are depicted by different line styles (see upper
right box).
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Table 1 | Parameters and variables used for the different actors in the RAAS.
Parameter/variable name Value Unit Reference
AGT
†
Molecular weight 53.15 kDa UniProt Consortium (2012)
Plasma concentration* 0.60 µmol ·L−1 In agreement with Kobori et al. (2009) and Wang et al. (2012),
consistent with the range given by Katsurada et al. (2007)
t1/2 11.29 min Optimization
kSecretion 7.81 L ·min−1 Optimization
RENIN
†
Molecular weight 48 kDa Sealey et al. (1980)
Plasma concentration* 3.62E−07 µmol ·L−1 Consistent with Juillerat et al. (1990), Nussberger et al. (2002)
kcat 3.60 min−1 Optimization
Km 5.04E−02 µmol ·L−1 Optimization
t1/2 1.44 min Optimization
ACE
Molecular weight 180 kDa Thevananther and Brecher (1999)
k+ 35.16 L ·µmol−1 ·min−1 Results from IV Ena model
k− 2.15E−02 min−1 Results from IV Ena model
kcat 4.48E−04 min−1 Optimization
Km 4.12E−03 µmol ·L−1 Optimization
Ang1
†
Molecular weight 1.30 kDa Wang et al. (2012)
Plasma concentration* 7.91E−06 µmol ·L−1 Consistent with Juillerat et al. (1990), Nussberger et al. (2002)
t1/2 0.72 min Optimization
Ang2
†
Molecular weight 1.05 kDa Noda et al. (2006)
Plasma concentration* 4.84E−06 µmol ·L−1 Consistent with Juillerat et al. (1990), Nussberger et al. (2002)
Log P −1.7 – Wang et al. (2012)
K inhibition 1.87E−08 µmol ·L−1 Optimization
t1/2 1.54 min Consistent with Boyd et al., 1967)
AT1
Molecular weight 41 kDa UniProt Consortium (2012)
CRef 7.69 µmol ·L−1 Optimization
k+ 23.50 L ·µmol−1 ·min−1 Optimization
k− 3.07E−02 min−1 Optimization
ALDOST
†
Molecular weight 0.36 kDa Wang et al. (2012)
Plasma concentration* 2.07E−04 µmol ·L−1 Consistent with Juillerat et al. (1990), Nussberger et al. (2002)
Log P 1.08 – Wishart et al. (2009)
Protein binding 50 % Pardridge (2011)
kProduction 1.51E−06 µmol ·min−1 Optimization
kSecretion 7.81 L ·min−1 Optimization
t1/2 12.87 min Optimization
PRORENIN
†
Molecular weight 57 kDa Sealey et al. (1980)
Plasma concentration* 1.21E−06 µmol ·L−1 Based on Tu et al. (2012) with a concentration of 69 pg ·ml−1
Renal plasma concentration intracellular 1.1E−04 µmol ·L−1 Optimization
VMaxKid 1.62 µmol ·min−1 ·L−1 Optimization
KmKid 4.68E−02 µmol ·L−1 Optimization
kSecretion 4.68E−02 L ·min−1 Optimization
V Kidney (intracellular volume kidney) 0.24 L PK-Sim®
t1/2 5.07 min Optimization
CARBOXYLESTERASE
KmLiv 710 µmol ·L−1 Tabata et al. (1990), Abu-Zahra and Pang (2000)
*Plasma concentration in venous blood at pre-administration steady state.
†Are assumed to circulate only in the plasma.
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Table 2 | Physicochemical and PK properties of enalapril and enalaprilat.
Enalapril Enalaprilat Unit Reference
Molecular weight 376.5* 348.4* g ·mol−1 Wang et al. (2012)
Log P 0.07* −0.74* Log units Ranadive et al. (1992), Remko (2007)
pKa 3.74 (4.75*) 2.03* – Remko (2007)
4.03*
Plasma protein binding 45 (50*) 50–60 (50*) % Sirianni and Pang (1998), Knox et al. (2011)
Hepatic clearance 354 – ml ·min−1 Noormohamed et al. (1990)
Renal clearance 18 8–9.5 L ·h−1 Dhareshwar (2007)
*Values used in the model.
Table 3 | Population specific information about subjects, optimized parameters, and model specific parameters.
Biollaz et al. (1982) Gu et al. (2004) Lee et al. (2003) Lu et al. (2009) Najib et al. (2003) Noormohamed
et al. (1990)
No. of individuals 12 20 12 20 24 12
Male/female 12/0 – – 20/0 24/0 12/0
Age (years) 22–33 – – – 23.25±4.55 21–25 (mean 22)
Weight (kg) – – – – 73.38±9.39 56–80 (mean 70)
Height (cm) – – – – 175.96±7.66 –
Healthy Yes Yes Yes Yes Yes Yes
Dose (mg) 10 10 20 2 ·5* 20 20
Fasted Yes No No Yes Yes Yes
OPTIMIZATION RESULTS
VmaxLiv (µmol ·min−1 ·L−1)† 184.87 178.18 131.88 148.05 146.50 194.36
Renal clearance Ena (L ·min−1 · kg−1) 6.02E−03 4.51E−3 6.53E−03 5.02E−03 4.61E−03 5.50E−03
Renal clearance Enaat (L ·min−1 · kg−1) 2.99E−04 8.01E−4 4.99E−04 6.30E−04 6.37E−04 6.21E−04
ACE ref conc. (CRef) (µmol ·L−1) 2.59 1.86 4.32 1.30 2.14 4.15
PARAMETERS OBTAINED FROM PK-Sim® ACCORDINGTO DIFFERENT AGE GROUPS
V Liver (L) 1.56 1.57 1.57 1.35 1.49 1.42
*Two enalapril maleate capsules were administered at the same time, containing 5mg enalapril each.
†VmaxLiv values for carboxylesterase enzyme and the conversion from Ena to Enaat in Eq. 8.
ACE inhibitors (ACEIs),
Direct renin inhibitors (DRIs),
Angiotensin-2-receptor-blockers (ARBs),
Aldosterone synthase inhibitors (ASIs), and
Potassium sparing diuretics.
A common drug of the first type of inhibitors is enalaprilat (Enaat),
a potent and reversible ACE inhibitor (MacFadyen et al., 1993;
Dhareshwar, 2007). Enaat is poorly absorbed from the gastroin-
testinal tract. Therefore, an ethyl ester promoiety was incorporated
within the administered parent drug enalapril (Ena) to increase
its oral bioavailability. After absorption of inactive Ena by the
peptide carrier-mediated transport system in the intestine, the
prodrug Ena is converted to Enaat by the carboxylesterase fam-
ily of enzymes activating it for ACE inhibition (MacFadyen et al.,
1993; Dhareshwar, 2007).
MATERIALS AND METHODS
A model of the RAAS based on available information was estab-
lished (Eissing et al., 2011). To evaluate the RAAS model, a
generic PBPK model of Ena and Enaat was developed and val-
idated with clinical data that was then coupled to the RAAS
model.
SOFTWARE
The RAAS model was created using the Systems Biology soft-
ware suite that consists of the wb PBPK software tool PK-Sim®
(Version 4.2, Bayer Technology Services, Leverkusen, Germany)
and the general purpose modeling software MoBi® (Version 2.3,
Bayer Technology Services, Leverkusen, Germany). This soft-
ware has successfully been applied for diverse modeling stud-
ies in laboratory animals and humans (Willmann et al., 2003,
2004, 2007, 2010; Edginton et al., 2006a,b,c, 2008; Brochot et al.,
2010; Eissing et al., 2011). The parameter identifications for
MoBi models were done using MATLAB® (R2010b, The Math-
Works, Inc., Natick, MA, USA) and the MoBi Toolbox for MAT-
LAB. Identification algorithm for Ena and Enaat models was
Monte Carlo, while RAAS identification algorithm was fmin-
search (fminsearch uses the Nelder–Mead Simplex method). The
identification error function was in both cases error root mean
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Table 4 | Reference expression values of ACE per organ as included in
PK-Sim 5® expression database (Meyer et al., 2012) from Unigene
(2010).
Name ACE AT1
Gene ID 1636 185
Hs 654434 477887
Organ Expression ERef in% (absolute
value) of highest expression value
Brain 15 (12.96) 5 (0.20)
Fat 6 (5.22) 0 (0)
Gonads 2 (2.01) 4 (0.16)
Heart 0 (0.16) 9 (0.35)
Kidney 0 (0.41) 100 (3.85)
Large Intestine 2 (1.44) 27 (1.04)
Liver 0 (0) 76 (2.94)
Lung 100 (86.38) 6 (0.22)
Muscle 0 (0.12) 8 (0.30)
Pancreas 0 (0.23) 0 (0)
Plasma 6 (5.55) 0 (0)
Skin 0 (0) 57 (2.19)
Spleen 0 (0) 89 (3.41)
Small Intestine 1 (0.32) 27 (1.04)
Stomach 3 (2.86) 0 (0)
square. For additional information, see the software manual or
http://www.systems-biology.com/products.
DEVELOPMENT OF THE RAAS-PBPK MODEL
Physiological data presented in Table 1 contains the information
gained from the literature or, if not available by optimization based
on data for Ang1, Ang2, aldosterone, renin, prorenin, ACE, AGT,
and the AT1. Optimization was done with the overall coupled
model and with all RAAS parameters (Table 1) simultaneously. For
each of them an individual PBPK model was developed which con-
tains many physiological background parameters (Eissing et al.,
2011) that are derived from the few input parameters presented in
Table 1. Mass transfer within the plasma (r1) between organs is
calculated as organ specific blood flow (Qorgan) times the drug con-
centration within the plasma of the respective organ (Cpls_organ)
times the overall plasma fraction (1−HCT) which is one sub-
tracted by the hematocrit (HCT) value. Passive transport into the
interstitial and intracellular space is realized by multiplying organ
specific partition coefficients K org.
r1 = Qorgan · (1−H CT) · Cpls_organ (1)
The interactions in the coupled model were described as
depicted in Figure 1 reflecting the biological processes as detailed
in the following. AGT, prorenin, renin, and aldosterone are the
four hormones and enzymes synthesized in cells and then secreted
endocrinally. It was assumed that these hormones and enzymes
are produced intracellular and secreted into the plasma by a
first order rate (r2 in µmol ·min−1) proportional to the intra-
cellular concentration (CCellularHormone) in the respective organ
with the rate constant kSecretion (in L ·min−1). The renin secre-
tion r3 (µmol ·min−1) is described by a “competitive” inhibition
equation including the conversion of prorenin to renin influ-
enced by Ang2 (see Figure 1), describing the conversion from
prorenin to renin, and simultaneously describing the secretion
from intracellular to plasma compartment of the kidney:
r3 = VMaxKid · VKidney · CProrenin (t )
CProrenin (t )+ KmKid ·
(
1+
(
CAng2(t )
Kinhibition
)) (2)
KmKid and VMaxKid are the respective enzymatic activity con-
stants,V kidney is the intracellular volume of the kidney,CProrenin is
the renal intracellular prorenin concentration (parameters under
prorenin in Table 1). K inhibition represents the inhibitory constant
for Ang2 andCAng2 is the renal plasma concentration of Ang2. The
degradation rate r4 (µmol ·min−1 · L−1) is described by Guillaud
and Hannaert (2010):
r4 = C (t ) ·
(
ln 2
t1/2
)
(3)
t 1/2 determines the half-life and C(t ) being the respective plasma
concentration over time. These half-lives were optimized for the
hormones and enzymes (see Table 1). The conversion of AGT
to Ang1 and from Ang1 to Ang2 take place in the plasma com-
partments of all organs (Eissing et al., 2011) and is an enzymati-
cally regulated process described by a Michaelis–Menten equation
(Gould et al., 1980; Ehlers and Kirsch, 1988). The change of hor-
mone mass over time (r5 in µmol ·min−1) then depends on the
enzyme concentration (C0) and the prohormone (CProhormone)
concentration in the respective organs, as well as on the enzyme
activity represented by theKm and kcat of the enzyme (Meyer et al.,
2012). This can be expressed by:
r5 = kcat · V0 · C0 (t ) · CProhormone (t )
CProhormone (t )+ Km (4)
The calculation refers to the respective organ plasma volumes
V 0 in L (taken from PK-Sim® database). ACE is most notably
bound to the endothelium (Dzau et al., 2001) and thus not circu-
lating in the model. The concentration of ACE and AT1 in each
organ (C0) is calculated via a reference concentration (CRef , see
Table 3) times the percentage of reference expression (ERef) from
literature (see Table 4, factor ERef = 100 for the highest expression
value):
C0 = CRef · ERef
100
(5)
Ang2 binds to the AT1 receptor, which influences the aldosterone
secretion. AT1 binding rate (r7 inµmol ·min−1 · L−1) is described
by a typical equation with k+ and k− binding constants for asso-
ciation and dissociation and the respective concentrations for AT1
(C0), Ang2 (C2), and the AT1-Ang2 complex (CComplex):
r7 = (k+ · C0 · (t ) · C2 (t ))−
(
k_ · Ccomplex (t )
)
(6)
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FIGURE 2 | (A) Plasma concentration-time profiles of Enaat after IV
Enaat administration. The solid blue line is the simulation result
compared to the data of Hockings et al. (1986) which are indicated as
points (adolescents) and triangles (elderly). (B) The simulated versus
observed plot for the same simulation with the Hockings data are
shown, indicated as points (adolescents) and triangles (elderly). The solid
black regression line denotes the line of identity (observed outcome is
equal to simulated outcome).
The AT1 concentrations were calculated as explained in Eq.
6, the respective relative expression values (ERef) are shown in
Table 4, and the reference concentration (CRef) is presented in
Table 1. As shown in Figure 1 AT1 is membrane bound too and
thereby does not circulate in the plasma. Aldosterone synthesis (r8
in µmol ·min−1) in our model was directly linked to the com-
plex formation of Ang2 bound to the AT1 (CComplex), which is
modeled as
r8 =
(
ksecretion · Ccomplex (t )
)+ kproduction (7)
The secretion is thereby described to be dependent on intracellu-
lar concentration of Ang2 receptor complex multiplied by the rate
constant kSecretion (in L ·min−1) and additionally represents the
continuous secretion as kProduction (Veldhuis et al., 2008).
DEVELOPMENT OF THE ENALAPRIL/ENALAPRILAT PBPK MODEL
A PBPK model for oral Ena including the metabolism to active
Enaat was developed first and used as test case for the dynamic
behavior of the RAAS model. Based on intravenous (IV) data,
parameters for Enaat were determined and then used in the parent-
metabolite model. The required physicochemical input properties
and clearance processes for the model are presented in Table 2.
The model simulations for oral Ena were compared to differ-
ent experimental data (Biollaz et al., 1982; Noormohamed et al.,
1990; Nussberger et al., 2002; Lee et al., 2003; Najib et al., 2003;
Gu et al., 2004; Lu et al., 2009). The six different subject and
dataset properties (all included to the respective simulations) are
shown in Table 3. Only the five parameters presented in Table 3
were optimized with MATLAB®. The respective IV Enaat sim-
ulations were compared to experimental data of Enaat plasma
concentrations after IV Enaat (Hockings et al., 1986) administra-
tion. The coupling of parent and metabolite was realized with a
hydrolytic reaction in the hepatocytes (Dhareshwar, 2007). This
reaction is mediated by different carboxylesterase enzymes. Km
values for metabolism to Enaat in Table 1 were taken from mea-
surements in rat hepatocytes (Tabata et al., 1990; Abu-Zahra and
Pang, 2000). The conversion rate (r9 in µmol ·min−1) from Ena
into Enaat in the hepatocytes with the respective intracellular
volume V Liver (see Table 3), the concentrations of Ena (CEna)
and Enaat (CEnaat) is modeled by Michaelis–Menten kinetics:
r9 = Vmax Liv · VLiver · CEna (t )
CEna (t )+ KmLiv (8)
The respective parameters for Michaelis–Menten kinetics are
VMaxLiv and KmLiv.
ASSEMBLING OF THE MODELS TO A FULL DYNAMIC PBPK-RAAS
MODEL
To couple the drug model to the full RAAS model the MoA
was included. Enaat binds to ACE in the RAAS (see Table 1,
ACE parameters) generating an inactive complex. The forma-
tion rate of Enaat-ACE complex (CComplex) is realized as pre-
sented in equation 6 for all plasma compartments. ACE con-
centration is based on the relative expression value in Table 4
which was obtained from Unigene (2010) and processed as
described in Meyer et al. (2012). The inhibition of ACE occurs
by ACE binding to Enaat, forming an ACE-Enaat- complex,
thereby blocking ACE for the interaction with Ang1. The
binding is implemented in the plasma compartment of each
organ.
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FIGURE 3 | (A) Exemplary plasma concentration-time curves of Ena and
Enaat from the coupled Ena-Enaat model after oral Ena application compared
to experimental data (Gu et al., 2004). The red solid line is the simulated Ena
plasma concentration, while the blue solid line is the simulation result of
Enaat. The respective data of Ena are indicated as circles, of Enaat as
triangles. (B) Simulated versus observed plot for Enalapril from the coupled
model, compared to the data by Biollaz et al. (1982), Noormohamed et al.
(1990), Lee et al. (2003), Najib et al. (2003), Gu et al. (2004), Lu et al. (2009),
with SD. The solid black regression line denotes the line of identity (observed
outcome is equal to simulated outcome). (C) Predicted versus observed plot
for Enalaprilat from the coupled Ena-Enaat model, compared to the data by
Biollaz et al. (1982), Noormohamed et al. (1990), Lee et al. (2003), Najib et al.
(2003), Gu et al. (2004), Lu et al. (2009).The solid black regression line denotes
the line of identity (observed outcome is equal to simulated outcome).
RESULTS
ORAL ADMINISTRATION OF ENALAPRIL
A PBPK model of IV Enaat has been developed with the data
indicated in Table 2. In Figure 2 the resulting PK-simulations for
IV Enaat are shown and the goodness-of-fit of the model based
on data is depicted (Hockings et al., 1986). This model was used
to determine the parameters related to Enaat, which are log P,
Molecular weight, pKa, plasma protein binding and clearance (see
Table 2). Additionally the constants of ACE binding were iden-
tified (see Table 1). The constant for association is much higher
than the dissociation constant, as stated by Reynolds (1984). This
parameterization was used within the coupled model without
changes.
Resulting plasma concentrations of ACE based on the explained
calculation (peripheral venous plasma concentration in the model
validated by data from Gu et al. (2004): 7.17E−4µmol · L−1)
correspond nicely with literature data of 2.52E−3µmol · L−1 by
Brice et al. (1995). After integrating the metabolite model into the
oral model, the coupled model exhibits the behavior presented
in Figure 3. Including the population dependent parameters for
the different publications (see Table 3), the six model simulations
show excellent agreement with the data. The serum concentration
profile of Enaat exhibits a prolonged terminal phase, apparently
representing the small fraction of the administered dose that has
been bound to ACE. As obvious from Figure 3, the model Ena
simulations and Enaat predictions accurately fit the observed data.
RAAS INHIBITION BY ENALAPRILAT
The PBPK model for the circulating, endocrine RAAS was devel-
oped to describe the steady state described in literature. It corre-
sponds to the pre-administration steady state discussed further
in the following. The model for Ena was then coupled to the
RAAS model to explore the dynamical behavior of the system
under inhibition. In Figure 4 the results for the full RAAS model
under administration of 10 mg Ena are shown at t = 1500 min
(administration at t = 1500 indicated by the red arrow). All para-
meters of the Ena-Enaat model were used without changes. The
pre- and post-administration steady states as well as the dynam-
ical transition after administration at t = 1500 min (red arrow)
show excellent agreement to literature data (Table 1, Figure 4A).
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FIGURE 4 | (A) Plasma concentration-time curves of hormones
included into the RAAS. Hormones are in a steady state until
administration of oral Ena at t = 1500 min indicated by the red arrow.
The respective data are indicated by different symbols (Nussberger
et al., 2002). (B) Simulated versus observed plasma concentrations
of different actors of the RAAS before and after inhibition of ACE by
Ena. The different hormones are depicted by different symbols
(Nussberger et al., 2002) with their SD. The solid black regression
line denotes the line of identity (observed outcome is equal to
simulated outcome).
In detail, Figure 4 shows the MoA of Ena. After the administra-
tion of Ena, ACE is inhibited. As can be seen, the conversion of
Ang1 to Ang2 is inhibited, lowering the Ang2 and aldosterone
plasma levels. The negative feedback loop from the Ang2 to the
renin synthesis is inhibited, leading to an increase of the renin
plasma concentration, and thereby the Ang1 levels. The compar-
ison of these induced changes in plasma levels by a scatter plot
(Figure 4B) to study data from Nussberger et al. (2002) shows
good agreement and corresponds also to older experimental data
(Given et al., 1984; Johnston et al., 1984; Juillerat et al., 1990; Azizi
et al., 1997).
The simulation of exemplary Ena administration shows,
that the full dynamical behavior of inhibition and the other
RAAS-hormone levels can be represented accurately (see
Figure 4).
DISCUSSION
A full mechanistic model of the circulating RAAS was developed.
The model represents the steady state and dynamic behavior of
the RAAS in an accurate manner. This was demonstrated by sim-
ulating the effects of representative drug acting on the system. The
Ang1 concentration is influenced by different reactions, Ang1 gen-
eration, Ang2 generation, degradation of Ang1, which lead to the
pre-administration steady state. So it is rather difficult to evalu-
ate the condition of substrate excess for the second, since the new
generation of Ang1 is fast. In addition the reference concentra-
tions C0 are artificial constructs in a product with kcat, where both
and Km are fitted parameters. Thus Michaelis–Menten equations
were used, although the C0 is much higher than the Ang1 con-
centration for the steady state, as it was used for these enzymes
to catalyze this reaction in the described way (Ehlers and Kirsch,
1988; Guillaud and Hannaert, 2010). Although we find an excellent
correlation of plasma levels and a good correlation of parameters
to the articles cited before, it has not been proven in this arti-
cle, that the optimized parameter values are unique to reach the
reference data, since not for all parameters measured values are
available. The Ena model was validated independently from the
parameterization of the RAAS and can thus also serve as a valida-
tion for the RAAS. Following the development of the Ena model
based on literature data, subsequently only population dependent
parameters were changed (listed in Table 3) to represent physiolog-
ical differences in the studies. After coupling to the RAAS model
the overall model was able to represent detailed information of
all main components and predict circulating plasma concentra-
tions of all included hormones by one coupled PBPK/PD model.
The excellent representation of the hormone levels at steady state
and during inhibition, implicate a good representation of the
underlying physiological processes in the RAAS.
The detailed physiological representation of relevant processes
spanning from wb distribution to molecular interactions allows
for, e.g., a mechanistic implementation of independent knowl-
edge on drug-target interactions, and thereby an integration and
translation of available knowledge.
Thus the model constitutes a first major step to establish a
PBPK-PD-model for drugs acting on blood pressure and heart
rate. Generally blood pressure and heart rate represent the state
of the art endpoint in clinical studies. Currently blood pressure
is not yet included in the model. The inclusion of inhibitors
from other classes of MoA’s can be used to explore pharmaco-
dynamic effects in the same model framework. Further extensions
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of this model and an inclusion of the dynamic behavior of the
blood pressure in response to changes in RAAS would allow
a full mechanistic representation of the PBPK-PD relationship
in cardiovascular diseases. Such a model could thus rational-
ize treatment decisions in the area of cardiovascular diseases.
By inclusion of a full process description from administration
of a drug to its effect, i.e., the lowering of blood pressure,
such a model allows to support cardiovascular drug research
from target identification and validation to dosing regimen
decision.
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